Strata Oncology Expands Sentinel Trial with Lehigh Valley Topper Cancer Institute and University of Michigan Health Rogel Cancer Center to Bring Precision Therapies to Patients Earlier in Their Cancer Journey – QNT Press Release

[ad_1]

100,000-patient prospective, observational study to evaluate ctDNA-based minimal residual disease (MRD) testing

ANN ARBOR, Mich., June 23, 2022 /PRNewswire/ — Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced that Lehigh Valley Topper Cancer Institute and the University of Michigan Health Rogel Cancer Center have joined as clinical trial sites in the Strata Sentinel™ trial, a prospective, observational study of the StrataMRD^TM minimal residual disease test that has the potential to shift the paradigm of cancer care, bringing the use of biomarker-matched precision therapies to earlier stages of the disease.

“The Strata Sentinel trial is a key piece of our strategy of developing integrated solutions to enable smarter and earlier cancer treatment,” said Dan RhodesPhD, co-founder and Chief Executive Officer, Strata Oncology. “We are grateful to add Lehigh Valley Topper Cancer Institute and the University of Michigan Health Rogel Cancer Center to our…

Full story available on Benzinga.com

[ad_2]

Source link